查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2090957

2026-2034年全球已通過核准學名藥市場規模、佔有率、趨勢和成長分析報告

Global Authorized Generics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 159 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球核准學名藥市場預計將從2025年的84.2億美元成長至2034年的152.6億美元，2026年至2034年的複合年成長率（CAGR）為6.83%。該市場正經歷強勁成長，這主要得益於醫療保健系統日益重視在維持高品質標準和療效等效性的同時，提供價格合理的藥品。核准學名藥為患者提供價格較低的替代藥物，這些藥物均在原廠藥的批准下生產，有助於擴大治療的可及性。對經濟實惠藥品的需求不斷成長以及降低成本的壓力日益增大，正在推動全球學名藥行業的成長。

專利到期、推廣學名藥的政策以及有利的法規結構是推動市場發展的關鍵因素。製藥公司正利用已核准的學名藥來延長產品生命週期，同時保持市場競爭力。日益增強的健康意識、藥品可及性的提高以及公共醫療保健項目需求的成長，持續為多個治療領域的行業持續成長創造有利條件。

隨著世界各國政府大力推廣可負擔的醫療保健並鼓勵更多使用學名藥的成長速度將加快。製藥公司之間日益激烈的競爭將推動生產效率提升和供應鏈最佳化的創新。專利的持續到期、醫療體系改革以及為提高藥品可及性而不斷加大的力度，預計將為獲得許可的學名藥行業創造巨大的長期機會。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球已通過核准學名藥市場：依治療領域分類

  • 市場分析、洞察與預測
  • 心血管系統
  • 中樞神經系統（CNS）
  • 抗感染藥物
  • 腫瘤科及支持性治療
  • 內分泌/代謝
  • 呼吸系統
  • 其他

第5章 全球已通過核准學名藥市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 腸外
  • 外用
  • 吸入
  • 其他

第6章 全球已通過核准學名藥市場：按分銷管道分類

  • 市場分析、洞察與預測
  • 零售藥房
  • 醫院藥房
  • 網路藥房
  • 其他

第7章 全球已通過核准學名藥市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Amneal Pharmaceuticals Inc
    • GSK Plc
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Padagis LLC
    • Pfizer Inc
    • Prasco LLC
    • Sandoz AG
    • Teva Pharmaceutical Industries Ltd
    • Viatris Inc
簡介目錄
Product Code: VMR112118907

The global authorized generics market size is expected to reach USD 15.26 Billion in 2034 from USD 8.42 Billion in 2025, growing at a CAGR of 6.83 during 2026-2034.This market is experiencing healthy expansion as healthcare systems increasingly prioritize affordable medicines while maintaining high standards of quality and therapeutic equivalence. Authorized generics provide patients with lower-cost alternatives manufactured under the original branded drug authorization, supporting broader treatment accessibility. Growing demand for cost-effective pharmaceutical products and increasing pressure to reduce healthcare expenditure are strengthening industry growth worldwide.

Patent expirations, expanding generic substitution policies, and favorable regulatory frameworks are major drivers supporting market development. Pharmaceutical companies are utilizing authorized generics to extend product life cycles while maintaining competitive market presence. Rising healthcare awareness, improved medicine accessibility, and increasing demand from public healthcare programs continue creating favorable conditions for sustained industry expansion across multiple therapeutic categories.

Future growth is expected to accelerate as governments promote affordable healthcare and encourage greater adoption of generic medicines. Increasing competition among pharmaceutical manufacturers will stimulate innovation in manufacturing efficiency and supply chain optimization. Continued patent expirations, healthcare reforms, and expanding pharmaceutical access initiatives are anticipated to create significant long-term opportunities for the authorized generics industry.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Area

  • Cardiovascular
  • CNS
  • Anti-infectives
  • Oncology & Supportive Care
  • Endocrine & Metabolic
  • Respiratory
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Inhalation
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

COMPANIES PROFILED

  • Amneal Pharmaceuticals Inc., GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Padagis LLC, Pfizer Inc., Prasco LLC, Sandoz AG, Teva Pharmaceutical Industries Ltd., Viatris Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTHORIZED GENERICS MARKET: BY THERAPY AREA 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Therapy Area
  • 4.2. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Anti-infectives Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Oncology & Supportive Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Endocrine & Metabolic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Respiratory Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTHORIZED GENERICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTHORIZED GENERICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AUTHORIZED GENERICS MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Therapy Area
    • 7.2.2 By Route Of Administration
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Therapy Area
    • 7.3.2 By Route Of Administration
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Therapy Area
    • 7.4.2 By Route Of Administration
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Therapy Area
    • 7.5.2 By Route Of Administration
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Therapy Area
    • 7.6.2 By Route Of Administration
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL AUTHORIZED GENERICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Amneal Pharmaceuticals Inc
    • 9.2.2 GSK Plc
    • 9.2.3 Hikma Pharmaceuticals PLC
    • 9.2.4 Lupin Limited
    • 9.2.5 Padagis LLC
    • 9.2.6 Pfizer Inc
    • 9.2.7 Prasco LLC
    • 9.2.8 Sandoz AG
    • 9.2.9 Teva Pharmaceutical Industries Ltd
    • 9.2.10 Viatris Inc